ORIGINAL ARTICLE
The potential prognostic role of peritumoral eosinophils within whole tumor-associated inflammatory cells and stromal histological characteristics in colorectal cancer
,
 
,
 
,
 
 
 
More details
Hide details
1
Department of Pathology, Baskent University Istanbul Hospital, Istanbul, Turkey
 
2
Department of Pathology, Istanbul Medipol University Hospital, Istanbul, Turkey
 
3
Department of Pathology, Istanbul Training and Research Hospital, Istanbul, Turkey
 
4
Department of Medical Oncology, Istanbul Medipol University Hospital, Istanbul, Turkey
 
5
Department of General Surgery, Istanbul Medipol University Hospital, Istanbul, Turkey
 
 
Submission date: 2020-05-15
 
 
Final revision date: 2020-07-21
 
 
Acceptance date: 2020-09-08
 
 
Publication date: 2020-10-25
 
 
Pol J Pathol 2020;71(3):207-220
 
KEYWORDS
TOPICS
ABSTRACT
We aimed to determine the prognostic role of whole tumor-associated inflammatory cells, especially eosinophils, and stromal histological characteristics in relation to other prognostic parameters in patients with colorectal carcinoma (CRC). A total of 122 patients who underwent an operation for CRC were included in this retrospective study. Conventional (tumor grade, TNM stage and venous invasion [VI]) and other histopathological (intratumoral/peritumoral budding [ITB/PTB], desmoplasia) tumor parameters were recorded and classified by density, as were the tumor-associated inflammatory parameters (intratumoral/peritumoral lymphocytes [ITL/PTL], eosinophils [IE/PTE], overall inflammation [ITI/PTI], Crohn-like inflammation [CLI]). Cancer-specific survival data were analyzed with respect to all tumor parameters. High ITB and PTB were significantly correlated with a higher rate of pT4, VI and desmoplasia (p < 0.05). An association of moderate ITL and extensive PTL with lesser likelihood of VI and metastasis; an association of extensive CLI with a significantly lower rate of metastasis and TNM stage IV; and minimal PTE with a significantly higher rate of pT4 stage, metastasis and ITB were detected (p < 0.05 for each). Our findings revealed that low score tumoral budding and an increase in tumor-related inflammation were associated with lesser likelihood of poor prognostic tumor parameters. Nonetheless, given the association of an increase in PTE with lesser likelihood of ITB, pT4, metastasis, and with non-significantly for better survival rates, our findings emphasize the potential role of peritumoral eosinophils as an additional prognostic parameter in CRC.
REFERENCES (43)
1.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival and risk factors. Gastroenterology Rev 2019; 14: 89-103.
 
2.
Lee CH, Tseng PL, Tung HY, et al. Comparison of risk factors between colon cancer and rectum cancer in a single medical center hospital, Taiwan. Arch Med Sci 2020; 16: 102-111.
 
3.
Malyarchuk BA, Grzybowski T, Derenko MV, et al. Mitochondrial DNA variability in Poles and Russians. Ann Hum Genet 2002; 66: 261-283.
 
4.
Mohammed F, Rezaee Khorasany AR, Mosaileby E, et al. Mitochondrial A12308G alteration in tRNA(Leu (CUN)) in colorectal cancer samples. Diagn Pathol 2015; 10: 115.
 
5.
Kumar B, Bhat ZI, Bansal S, et al. Asscociation of mitochondrial copy number variation and T16189C polymorphism with colorectal cancer in North Indian population. Tumour Biol 2017; 39: 1010428317740296.
 
6.
Webb E, Broderick P, Chandler I, et al. Comprehensive analysis of common mitochondrial DNA variants and colorectal cancer risk. Br J Cancer 2008; 99: 2088-2093.
 
7.
Skonieczna K, Jawien A, Marszalek A, et al. Mitogenome germ-line mutations and colorectal cancer risk in Polish population. Arch Med Sci 2020; 16: 366-373.
 
8.
Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007; 13: 6862-6870.
 
9.
Barresi V, Reggiani Bonetti L, Ieni A, et al. Poorly differentiated clusters: clinical impact in colorectal cancer. Clin Colorectal Cancer 2017; 16: 9-15.
 
10.
Harbaum L, Pollheimer MJ, Kornprat P, et al. Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol 2015; 28: 403-413.
 
11.
O’Connell JB, Maggard MA, Ko JY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425.
 
12.
Wang LM, Sheahan K. Prognostic markers in colorectal pathology: is morphology enough? Diag Pathol 2011; 17: 386-394.
 
13.
Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer 2009; 101: 1382-1392.
 
14.
Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38: 451-466.
 
15.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
 
16.
Pagès F, Mlenic B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391: 2128- 2139.
 
17.
Prizment AE, Vierkant RA, Smyrk TC, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study. Mod Pathol 2016; 29: 516-527.
 
18.
Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-2654.
 
19.
Briede I, Strumfa I, Vanags A, et al. The association between inflammation, epithelial mesenchymal transition and stemness in colorectal carcinoma. J Inflamm Res 2020; 13: 15-34.
 
20.
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual, 8th ed. Springer, New York 2017.
 
21.
Hamilton SR, Bosman FT, Boffetta P. Carcinoma of the colon and rectum. Bosman FT, Carneiro F, Hruban RH (eds.). World Health Organization classification of tumours of the digestive system. IARC, Lyon 2010; 131-181.
 
22.
Dawson H, Kirsch R, Driman DK, et al. Optimizing the detection of venous invasion in colorectal cancer: the Ontario, Canada, experience and beyond. Front Oncol 2015; 4: 354.
 
23.
Kirch R, Messenger D, Riddell R, et al. Venous invasion in colorectal cancer: Impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am J Surg Pathol 2013; 37: 200-210.
 
24.
Graham RP, Vierkant RA, Tillmans LS, et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 2015; 39: 1340-1346.
 
25.
Fernández-Ace¼ero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000; 88: 1544-1548.
 
26.
College of American Pathologists protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Based on AJCC/UICC TNM, 8th edition Protocol web posting date: February 2020 Available from: https://documents.cap.org/prot....
 
27.
Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 2012; 147: 366-371.
 
28.
Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect – a histopathological and immunohistochemical study. BMC Cancer 2001; 1: 7.
 
29.
Fisher ER, Paik SM, Rockette H, et al. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol 1989; 20: 159-163.
 
30.
McGinnis MC Jr., Bradley EL, Pretlow TP, et al. Correlation of stromal cells by morphometric analysis with metastatic behavior of human colonic carcinoma. Cancer Res 1989; 49: 5989-5993.
 
31.
Pretlow TP, Boohaker EA, Pitts AM, et al. Heterogeneity and subcompartmentalization in the distribution of eosinophils in human colonic carcinomas. Am J Pathol 1984; 116: 207-213.
 
32.
Richards CH, Flegg KM, Roxburgh CS, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012; 106: 2010-2015.
 
33.
Rao H, Chen J, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One 2012; 7: e30806.
 
34.
Akishima-Fukasawa Y, Ishikawa Y, Akasaka Y, et al. Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer. Histopathology 2011; 59: 470-481.
 
35.
Mizuno R, Kawada K, Itatani Y, et al. The role of tumor-asscociated neutrophils in colorectal cancer. Int J Mol Sci 2019; 20: 529.
 
36.
Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014; 110: 1595-1605.
 
37.
Kita H. Eosinophils: Multifaceted biological properties and roles in health and disease. Immunol Rev 2011; 242: 161-177.
 
38.
Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils:the unsung heroes in cancer? Oncoimmunology 2018; 7: e139134.
 
39.
Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008; 14: 1413-1417.
 
40.
Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15: 6412-6420.
 
41.
Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol 2012; 19: 3706-3712.
 
42.
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consesnsus Conference (ITBCC) 2016. Mod Pathol 2017; 30: 1299-1311.
 
43.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer – ready for diagnostic practice? Hum Pathol 2016; 47: 4-19.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top